2020-2027 Analysis and Review Potassium Clavulanate Market

Potassium Clavulanate Market

Potassium Clavulanate Market By Clinical Application (Acute Bacterial Sinusitis, Community Acquired Pneumonia and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

10-06-2020 REP-HC-5113 40 Tables 120 pages Format

The potassium clavulanate market was valued at USD 833.0 Mn by 2019. Rising prevalence of acute bacterial sinusitis infection across all age groups worldwide primarily drives the potassium clavulanate market growth. Additionally, the high mortality rate associated with community-acquired pneumonia further accelerates the demand for potassium clavulanate market growth.

Potassium Clavulanate Market

Potassium clavulanate is a beta-lactamase inhibitor that is frequently used in combination with other antibiotics such as amoxicillin, cefixime, and cefpodoxime to fight the antibiotic resistance by preventing the breakdown of antibiotics by the beta-lactamase enzymes, thereby ensuring their broad-spectrum bactericidal activity against bacterial infections.

The major segments related to the potassium clavulanate market are: 

By Clinical Application (2017–2027; US$ Mn)

Acute Bacterial Sinusitis

Community Acquired Pneumonia

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global potassium clavulanate market
  • The overall segmentation of the potassium clavulanate market, by clinical application, distribution channel, and geography is minutely studied. Acute bacterial sinusitis and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
  • Rising prevalence of acute bacterial sinusitis worldwide
  • A constant rise in the number of patients suffering from community-acquired pneumonia in the developing regions

Report gist?

  • The study of the global potassium clavulanate market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers a qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of potassium clavulanate due to the  rising prevalence of acute bacterial sinusitis worldwide
  • The report will benefit doctors treating patients suffering from community-acquired pneumonia by prescribing them with potassium clavulanate drug combinations
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to potassium clavulanate market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Acute bacterial sinusitis is spearheading the clinical application segment for the potassium clavulanate market. According to the latest statistics provided by the World Health Organization (WHO), acute bacterial sinusitis occurs in almost 90% of the patients previously suffering from viral upper respiratory tract infection. It affects the maxillary sinuses with the duration of symptoms being shorter than 4 weeks, the disease progression is usually related to some allergy or local irritant. Community-acquired pneumonia will be projecting impressive market growth during the forecast period on account of the rising prevalence of the disease in children below 5 years of age. As per the latest research citings presented by the National Institute of Health (NIH), the annual incidence rate of community-acquired pneumonia varies between 1.5 to 14 per 1000 people throughout the globe.

Hospital pharmacy presently dominating the distribution channel segment for potassium clavulanate market. The drug is used in combination with other antibiotics such as amoxicillin, cefixime, cefpodoxime, etc. hence, it is necessary for the hospital pharmacist to pay attention to the drug strength associated with potassium clavulanate while dispensing it as a combination drug therapy. Retail pharmacy is expected to highlight impressive market growth during the forecast period chiefly due to the sale of low-cost antibiotics due to government subsidy on essential medicine and its capacity to provide medicinal requirements on patients residing in remote locations.

North America is currently spearheading the geography segment for the potassium clavulanate market. Rising prevalence of acute bacterial sinusitis across all age groups primarily drives the market growth in the region. As per the recent research citings provided by the American College of Physicians (ACP), approximately 3 million hospital visits are reported in the United States associated with acute bacterial sinusitis. Affordable reimbursement scenario for the potassium clavulanate drug formulations further propels the market growth in the region. Europe is the second-largest regional segment for the potassium clavulanate market. The nurturing regulatory environment provided by the European Medical Agency for the sale and distribution of antibiotics containing potassium clavulanate determines the market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for potassium clavulanate market on account of the effective implementation of the treatment regimen pertaining to community-acquired pneumonia in the South East Asia region and flourishing generic drugs market.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.